1213040-80-2

Upstream product

• 1422510-21-1 C₁₃H₁₈ClNOS 
• 1422511-42-9 [N(E),S(S)]-N-[(3-chlorophenyl)methylene]-2-methyl-2-propanesulfinamide 
• 587-04-2 m-Chlorobenzaldehyde 
• 58824-53-6 1-(3-chlorophenyl)prop-2-en-1-ol 

Downstream Products

• 1375475-10-7 (S)-N-(1-(3-chlorophenyl)allyl)benzamide 
• 1422510-22-2 (S)-tert-butyl (1-(3-chlorophenyl)allyl)carbamate 
• 1314406-54-6 (S)-tert-butyl (1-(3-chlorophenyl)-3-hydroxypropyl)carbamate 
• 1422511-35-0 3-((tert-butoxycarbonyl)amino)-3-(3-chlorophenyl)propyl methanesulfonate 
• 1422510-20-0 tert-butyl (1-(3-chlorophenyl)-3-iodopropyl)carbamate 

Relevant academic research and scientific papers

CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS

The present invention provides compounds of Formula (Ia): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Direct, enantioselective iridium-catalyzed allylic amination of racemic allylic alcohols

The direct route: Iridium-catalyzed direct conversion of branched allylic alcohols into enantioenriched branched primary allylic amines is highly regio- and enantioselective (see scheme; coe=cyclooctene). Copyright